Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.1.137NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.446NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.76 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.398NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.163NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
P.3 (Theta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.254NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.39.1.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.418NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.9.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.40NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.122NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAJNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.431NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.168NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Q.6 (Alpha)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.41NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.527NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
C.18NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.500NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.147NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.487NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.68NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.121NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AA.5NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AS.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.115NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CJ.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BM.1.1.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
DE.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.1.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BQ.1.19NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.3.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.2.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.1.19NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.7.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.75.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BM.1.1.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBMNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.34NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CB.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BR.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CL.1.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.2.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CH.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
EF.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BR.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BE.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BF.7.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used